References
- Shifren JL, Gass ML. The North American Menopause Society Recommendations for Clinical Care of Midlife Women. Menopause 2014;21:1–25
- Hale GE, Robertson DM, Burger HC. The perimenopausal woman: endocrinology and management. J Steroid Biochem Mol Biol 2014;142:121–31
- Martin VT, Pavlovic J, Fanning KM, et al. Perimenopause and menopause are associated with high frequency headache in women with migraine: results of the American Migraine Prevalence and Prevention Study. Headache 2016;56:292–305
- Jones HJ, Huang AJ, Subak LL, et al. Bladder symptoms in the early menopausal transition. J Women’s Health 2016;25:457–63
- Santoro N. Perimenopause: from research to practice. J Women’s Health 2016;25:332–9
- American Congress of Obstetricians and Gynecologists, 2011. Women’s Health Stats and Facts. Accessed from: https://www.acog.org/-/media/NewsRoom/MediaKit.pdf on March 13, 2016
- Speroff L. The effect of aging on fertility. Curr Opin Obstet Gynecol 1994;6:115–20
- Steiner AZ, Jukic AM. Impact of female age and nulligravidity on fecundity in an older reproductive age cohort. Fertil Steril 2016;105:1584–8
- Guttmacher Institute, 2014. Unintended Pregnancy in the United States: Factsheet. Accessed from: https://www.guttmacher.org/pubs/FB-Unintended-Pregnancy-US.html on March 12, 2016
- Avis NE, Brockwell S, Randolph JF, et al. Longitudinal changes in sexual functioning as women transition through menopause: results from the Study of Women’s Health Across the Nation. Menopause 2009;16:442–52
- Finer L, Philbin J. Trends in ages at key reproductive transitions in the US, 1951–2010. Women’s Health Issues 2014;24:E271–9
- Curtin SC, Abma JC, Kost K. 2010 Pregnancy rates among U.S. women. NCHS health e-stat. Accessed from: https://www.cdc.gov/hchs/data/hestat/pregnancy/2010_pregnancy_rates.pdf
- Khalil A, Syngelaki A, Maiz N, et al. Maternal age and adverse pregnancy outcome: a cohort study. Ultrasound Obstet Gynecol 2013;42:634–43
- World Health Organization, 2015. Medical eligibility criteria for contraceptive use, 5th edn. Accessed from: http://www.who.int/reproductivehealth/publications/family_planning/MEC-5/en/
- Mendoza N, Soto E, Sanchez-Borrego R. Do women aged over 40 need different counseling on combined hormonal contraception? Maturitas 2016;87:79–83
- Maclennan AH. Evidence-based review of therapies at the menopause. Int J Evid Based Healthcare 2009;7:112–23
- Kase NG. Impact of hormone therapy for women aged 35 to 65, from contraception to hormone replacement. Gender Med 2009;6(Suppl1):37–59
- De Basos M, Stegeman BH, Rosendaal FR, et al. Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev 2014;3:CD010813
- Bassuk SS, Manson JE. Oral contraceptives and menopausal hormone therapy: relative and attributable risks of cardiovascular disease, cancer, and other health outcomes. Ann Epidemiol 2015;25:193–200
- James AH. Pregnancy-associated thrombosis. Hematol Am Soc Hematol Educ Program 2009;277–85
- National Cancer Institute, 2014. Probability of breast cancer in American women. Accessed from: http://seer.cancer.gov/statfacts/html/breast.html
- Brinton LA, Daling JF, Liff J, et al. Oral contraceptives and breast cancer risk among younger women. J Natl Cancer Inst 1995;87:827–35
- Marchbanks PA, McDonald JA, Wilson HG, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med 2002;346:2025–32
- Hannaford PC, Selvaraj S, Elliott AM. Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner’s oral contraception study. Br Med J 2007;335:651
- Beaber EF, Buist DS, Barlow WE, et al. Recent oral contraceptive use by formulation and breast cancer risk among women 20 to 49 years of age. Cancer Res 2014;74:4078–89
- Colquitt CW, Martin TS. Contraceptive methods: A review of nonbarrier and barrier products. J Pharm Pract 2015 June 1; pii: 0897190015585751. Epub ahead of print
- Williams JK. Contraceptive needs of the perimenopausal woman. Obstet Gynecol Clin North Am 2002;29:575–88
- Cantero Perez P, Klingemann J, Yaron M, et al. [Contraception during the perimenopause: indications, security (safety), and non-contraceptive benefits.] Rev Med Suisse 2015;11:1986, 1988–92
- Grimes DA, Lopez LM, O’Brien PA, Raymond EG. Progestin-only pills for contraception. Cochrane Database Syst Rev 2013 Nov 13;11:CD007541
- Raymond EG. Progestin-only pills. In Hatcher RA, Trussell J, Nelson AL, et al., eds. Contraceptive Technology, 20th edn. New York: Ardent Media, Inc., 2011:237–47
- Jacobstein R, Polis CB. Progestin-only contraception: injectables and implants. Best Pract Res Clin Obstet Gynaecol 2014;28:795–806
- Shulman LP. The use of triphasic oral contraceptives in a continuous use regimen. Contraception 2005;72:105–10
- Trussell J. Contraceptive efficacy. In Hatcher RA, Trussell J, Nelson AL, et al., eds. Contraceptive Technology, 20th revised edn. New York: Ardent Media, 2013:69–76
- Conti J, Shaw K. Update on long-acting reversible methods. Curr Opin Obstet Gynecol 2015;27:471–5
- Kaunitz AM, Darney PD, Ross D, et al. Subcutaneous DMPA vs intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density. Contraception 2009;80:7–17
- World Health Organization. Depot-medroxyprogesterone acetate (DMPA) and risk of endometrial cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Cancer 1991;49:186–90
- Bednarek PH, Jensen JT. Safety, efficacy and patient acceptability of the contraceptive and non-contraceptive uses of the LNG-IUD. Int J Womens Health 2010;1:45–58
- Sitruk-Ware R. The levonorgestrel intrauterine system for use in peri- and postmenopausal women. Contraception 2007;75(Suppl6):S155–S60
- Wildemeersch D. Why perimenopausal women should consider to use a levonorgestrel intrauterine system. Gynecol Endocrinol 2016 Mar 1; Epub ahead of print
- Long ME, Faubion SS, MacLaughlin KL, et al. Contraception and hormonal management in the perimenopause. J Women’s Health 2015;24:3–10
- Edelman A, Micks E, Gallo MF, et al. Continuous or extended cycle vs cyclic use of combined hormonal contraceptives for contraception. Cochrane Database Syst Rev 2014;7:CD004695
- Mendoza N, Sanchez-Borrego R. Classical and newly recognized non-contraceptive benefits of combined hormonal contraceptive use in women over 40. Maturitas 2014;78:45–50
- Dinger J, Minh TD, Buttmann N, Bardenheuer K. Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen. Obstet Gynecol 2011;117:33–40
- Shulman LP. The state of hormonal contraception today: benefits and risks of hormonal contraceptives: combined estrogen and progestin contraceptives. Am J Obstet Gynecol 2011;205(4Suppl):S9–S13
- Roura E, Traver N, Waterboer T, et al. The influence of hormonal factors on the risk of developing cervical cancer and pre-cancer: results from the EPIC Cohort. PLoS One 2016;25;11(1):e0147029
- How to make the switch from OC use to HRT. Contracept Technol Update 2000;21:33
- Baldwin MK, Jensen JT. Contraception during the perimenopause. Maturitas 2013;76:235–42
- Fritz MA, Speroff L. Clinical Gynecologic Endocrinology and Infertility, 8th edn. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins, 2011
- American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 141: Management of menopausal symptoms. Obstet Gynecol 2014;123:202–16